BridgeBio Pharma Inc. published a document analyzing state-level differences in the incidence of transthyretin amyloid cardiomyopathy (ATTR-CM) among United States veterans following the introduction of disease-modifying therapies. The document discusses geographic disparities in diagnosis rates and highlights the need for further investigation into factors such as access to cardiovascular care and disease awareness. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on September 28, 2025, and is solely responsible for the information contained therein.